SNSE
SENSEI BIOTHERAPEUTICS INC
1 day chart
About SNSE
Sensei Biotherapeutics, Inc. is an immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated Biologics (TMAb) platform, it develops therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. It also develops SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39.
Buy US stocks in Australia starting with SNSE. Open an account and start investing today!
$21.50M
-
0.00%
35.08K
$0.88
$0.77
$0.79
$1.93
$0.75
SNSE FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in SNSE
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.